Leonard Calabrese, DO

Closing Remarks

Video content above is prompted by the following:

Can each of you provide closing remarks on how you treat your own patients to achieve remission?

Videos

Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.

Safety and Efficacy of Janus Kinase Inhibitors

Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.

Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?

Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?

In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?

Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.

Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices

If a patient continues to cycle tumor necrosis factor inhibitors (TNFis) and does not achieve remission, how do complications, such as irreversible joint erosion, potentially affect patient quality of life?

With the wide range of treatment options, why do you think providers are continuing to choose a second or even a third TNFi after the first fails?

Are there access barriers to switching mechanism of action (MOA)? What are other barriers to care exist when switching to another MOA vs cycling a TNF?

What treatment considerations do you give to a patient who initially responds well to a TNFi but the response wanes over time?

Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.

Outcomes of Class Switching vs Cycling TNF Inhibitors

What outcomes are associated with switching to a biologic with a different mechanism of action (MOA) rather than cycling a tumor necrosis factor inhibitor (TNFi)?

Can you describe an anecdotal patient case in which the patient switched therapy to a different MOA? Did the switch happen after a few TNFis or after first TNFi

Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.

Leonard Calabrese, DO

Articles